Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

FDA approves Can-Fite's IND application for phase I study of CF-102 for liver cancer

Jan. 11, 2008

Nektar initiates phase II clinical program for PEG-Irinotecan in colorectal cancer

Jan. 11, 2008

ZymoGenetics initiates phase II trial of IL-21 with Nexavar for renal cell cancer

Jan. 10, 2008

Novel anticancer agents revealed in patent literature

Jan. 10, 2008

Coronado initiates phase I trial of fourth-generation doxorubicin analogue

Jan. 9, 2008

Exelixis initiates phase I/II trial of XL-184 for non-small cell lung cancer

Jan. 9, 2008

Allos initiates phase IIb study of PDX in patients with non-small cell lung cancer

Jan. 9, 2008

Recent patents impart new therapeutic agents for cancer

Jan. 9, 2008

Callisto restructures license agreement with Genzyme for atiprimod for carcinoid cancer

Jan. 8, 2008

Orphan drug designation granted for non-radiolabeled TM-601

Jan. 8, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...